請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/2616
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 吳明賢(Ming-Shiang Wu) | |
dc.contributor.author | Ting-Hsu Liu | en |
dc.contributor.author | 劉庭旭 | zh_TW |
dc.date.accessioned | 2021-05-13T06:43:12Z | - |
dc.date.available | 2019-03-01 | |
dc.date.available | 2021-05-13T06:43:12Z | - |
dc.date.copyright | 2017-03-01 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-02-08 | |
dc.identifier.citation | 1. Aldoori WH , Giovannucci EL , Rimm EB et al. A prospective study of diet and the risk of symptomatic diverticular disease in men . Am J Clin Nutr 1994 ; 60 : 757–64.
2. Bolster LT , Papagrigoriadis S . Diverticular disease has an impact on quality of life— results of a preliminary study . Colorectal Dis 2003; 5 : 320–3. 3. Bianchi M , Festa V , Moretti A et al. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease . Aliment Pharmacol Th er 2011 ; 33 : 902–10. 4. Clemens CH , Samsom M , Roelofs J et al. Colorectal visceral perception in diverticular disease . Gut 2004 ; 53 : 717–22. 5. Chang HY , Kelly EC , Lembo AJ . Current gut-directed therapies for irritable bowel syndrome. Curr Treat Options Gastroenterol 2006 ; 9 : 314–23. 6. Comparato G , Fanigliulo L , Aragona G et al. Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment? Dig Dis 2007 ; 25 : 252–9. 7. Crowe FL et al. Diet and risk of diverticular disease in Oxford cohort of European Prospective Investigation into Cancer and Nutrition (EPIC): prospective study of British vegetarians and nonvegetarians. BMJ 2011 ; 343 : d4131. 8. Cuomo R et al. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. Eur J Clin Invest. 2013 Nov;43(11) : 1147-55. 9. Dunlop SP , Jenkins D , Neal KR et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS . Gastroenterology 2003 ; 125 : 1651–9. 10. Di Mario F , Aragona G , Leandro G et al. Effi cacy of mesalazine in the treatment of symptomatic diverticular disease . Dig Dis Sci 2005 ; 50 :581–6. 11. Drossman DA , McKee DC , Sandler RS et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome . Gastroenterology 1988;95:701–8 12. Everhart et al. Burden of digestive disease in the United States part II: lower GI disease. Gastroenterology 2009; 136:741-54 13. Gatta L et al. Efficacy of 5-ASA in the treatment of colonic diverticular disease. J Clin Gastroenterol 2010;44: 113–9. 14. Gu HX et al. Organic colonic lesions in 3,332 patients with suspected irritable bowel syndrome and lacking warning signs, a retrospective case–control study. Int J Colorectal Dis 2011 ; 26 : 935–940 15. Gwee KA, Lu CL et al. Epidemiology of irritable bowel syndrome in Asia: Something old, something new, something borrowed. Journal of gastroenterology and hepatology. 2009; 24:1601-1607 16. Hjern F , Wolk A , Hakansson N . Obesity, physical inactivity, and colonic diverticular disease requiring hospitalization in women: a prospective cohort study . Am J Gastroenterol 2012 ; 107 : 296 – 302 . 17. Huizinga JD , Waterfall WE , Stern HS . Abnormal response to cholinergic stimulation in the circular muscle layer of the human colon in diverticular disease. Scand J Gastroenterol 1999 ; 34 : 683–8. 18. Hobson KG et al. Etiology and Pathophysiology of Diverticular Disease. Clin Colon Rectal Surg. 2004 August; 17(3) : 147–153. 19. Humes DJ , Simpson J , Neal KR et al. Psychological and colonic factors in painful diverticulosis . Br J Surg 2008 ; 95 : 195–8. 20. Halpin SJ , Ford AC . Prevalence of symptoms meeting criteria for irritablebowel syndrome in infl ammatory bowel disease: systematic review and meta-analysis . Am J Gastroenterol 2012 ; 107 : 1474–82. 21. Jung HK , Choung RS , Locke GR III et al. Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a populationbased study. Am J Gastroenterol 2010 ; 105 : 652–61. 22. Kondo S , Yamaji Y , Watabe H et al. A randomized controlled trial evaluating the usefulness of a transparent hood attached to the tip of the colonoscope. Am J Gastroenterol 2007 ; 102 : 75 – 81. 23. Lamiki P , Tsuchiya J , Pathak S et al. Probiotics in diverticular disease of the colon: an open label study . J Gastrointestin Liver Dis 2010 ; 19 : 31–6. 24. Nagata N et al. Alcohol and smoking affect risk of uncomplicated colonic diverticulosis in Japan. PLoS One. 2013 Dec 10;8(12):e81137. 25. Niikura R , Nagata N , Shimbo T et al. Colonoscopy can miss diverticula of the left colon identifi ed by barium enema. World J Gastroenterol 2013;19:2362 – 7 . 26. Painter NS , Truelove SC , Ardran GM et al. Segmentation and the localization of intraluminal pressures in the human colon, with special reference to the pathogenesis of colonic diverticula Gastroenterology 1965 ; 49 : 169–77. 27. Parks TG . Natural history of diverticular disease of the colon . Clin Gastroenterol 1975 ; 4 : 53–69. 28. Raskin JB . Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology 2014 Oct;147(4):793-802 29. Spiller RC. Role of infection in irritable bowel syndrome . J Gastroenterol 2007 ; 42 (Suppl 17) : S41–7. 30. Strate LL , Liu YL , Aldoori WH et al. Obesity increases the risks of diverticulitis and diverticular bleeding . Gastroenterology 2009 ; 136 : 115 – 22 31. Song JH, Kim YS, Lee JH, Ok KS, Ryu SH, et al. Clinical characteristics of colonic diverticulosis in korea: A prospective study. Korean J Intern Med 2010; 25: 140–146. 32. Strate LL et al. Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. Am J Gastroenterol. 2012 Oct ; 107(10) : 1486-93. 33. Sharara AI, El-Halabi MM, Mansour NM, Malli A, Ghaith OA, et al. Alcohol consumption is a risk factor for colonic diverticulosis. J Clin Gastroenterol. 2013 ; 47(5): 420-5 34. Sirinthornpunya S; Rungjiratananon S. Association of colonic diverticular disease and irritable bowel syndrome in Thai patients. Journal of the Medical Association of Thailand. 2014 Nov 97; Suppl 11 : S18-24,. 35. Talley NJ , Phillips SF , Wiltgen CM et al. Assessment of functional gastrointestinal disease: the bowel disease questionnaire . Mayo Clin Proc 1990 ; 65 : 1456–79. 36. Trepsi E , Colla C , Panizza P et al. Th erapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 year follow-up results . Minerva Gastroenterol Dietol 1999 ; 45 : 245–52. 37. Tursi A , Brandimarte G , Daffi na R . Long-term treatment with mesalazine and rifaximin vs. rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon . Dig Liver Dis 2002 ; 34 : 510–5. 38. Talley NJ Irritable bowel syndrome . Intern Med J 2006 ; 36 : 724–8. 39. Tursi A et al. Assessment and grading of mucosal inflammation in colonic diverticular disease. J Clin Gatroenterol.2008; 42 : 699-703. 40. Tursi A et al. Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis. 2009 Jan ; 24(1) : 49-55. 41. Tursi A , Papagrigoriadis S . Review article: the current and evolving treatment of colonic diverticular disease . Aliment Pharmacol Ther 2009 ; 30 : 532–46. 42. Tursi A et al. Moderate to severe and prolonged left lower-abdominal pain is the best symptom characterizing symptomatic uncomplicated diverticular disease of the colon: a comparison with fecal calprotectin in clinical setting. J Clin Gastroenterol. 2015 Mar;49(3):218-21. 43. Wang LH , Fang XC , Pan GZ . Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis.Gut 2004;53: 1096–101. 44. Wang C, Wang S, Qin J, Lv Y, Ma X, et al. Ethanol upregulates iNOS expression in colon through activation of nuclear factor-kappa B in rats. Alcohol Clin Exp Res 2010; 34: 57–63. 45. Yamada E et al. Association between the location of diverticular disease and the irritable bowel syndrome: a multicenter study in Japan. American Journal of Gastroenterology. 2014; 109(12):1900-5. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/2616 | - |
dc.description.abstract | 研究背景:
大腸激躁症(irritable bowel syndrome, IBS)是常見的腸胃道功能性疾病。大腸激躁症與一些器質性的疾病於臨床表現及病生理機轉有重疊的現象。在近來的研究發現,大腸憩室症(colonic diverticulosis, CD),特別是左側的大腸憩室症,有較高的風險會患有大腸激躁症。然而在亞洲人族群的研究中,有相衝突的結果發現,也缺乏大型前瞻性研究證實。慢性低度發炎及腸道微生物叢的改變在有症狀的大腸憩室疾病(diverticular disease, DD)的病生理機轉中扮演重要角色。近來許多研究探討使用5-ASA,抗生素或益生菌來治療慢性憩室疾病的效果。如何區分大腸激躁症與慢性有症狀的大腸憩室疾病以給予適當的治療實有其臨床上的重要性。腹痛持續大於24小時的這個臨床症狀曾被指出能鑑別大腸激躁症與有症狀的大腸憩室疾病,然而其有效性仍需要證實。 目的: 進行前瞻性研究以了解大腸激躁症與大腸憩室症之間的關聯性於台灣人族群中是否存在。驗證腹痛持續大於24小時的這個臨床症狀是否能鑑別大腸激躁症與有症狀的大腸憩室疾病。 方法: 針對於本院接受全大腸鏡檢查的病人進行收案。以問卷調查方式來診斷大腸激躁症(根據Rome III criteria) 並了解病人腹痛的特徵。比較IBS及non-IBS兩組病人間大腸憩室症(CD)的盛行率是否有差異。比較CD及non-CD兩組病人間IBS的盛行率是否有差異。比較單純只有IBS (pure IBS)及單純只有(有症狀)大腸憩室疾病(pure DD)的兩組病人間,腹痛持續大於24小時的這個臨床症狀的盛行率是否有差異。 結果: 本研究於2016年3月至11月間共收案1502人,其中119人因符合排除條件而被排除,最後有1383人進入結果分析。病人的平均年齡為55.8±13.1歲,男女比為1.58:1。收集的個案中6.6% 符合Rome III criteria中大腸激躁症(IBS)定義,17.1% 有大腸憩室症,以右側憩室症為主,佔所有憩室症中的69%。IBS及non-IBS兩組間不論是在總體(Diverticulosis, 14.3% vs 17.3%, P=0.455)、右側(RD, 8.8% vs 12.0%, P=0.359)或是左側(LD, 2.2% vs 2.6%, P=0.435)憩室症的盛行率都未達統計學上顯著差別。在IBS組中,有顯著較高的較BSRS-5 score。年輕(<65歲)的IBS族群中,有較少的大腸腺瘤(OR:0.43, P=0.012)。大腸憩室症(CD)及無大腸憩室症(non-CD)兩組間在IBS的盛行率上都無顯著差異(5.5% vs 6.8%, P=0.455)。在CD組中,年齡大是最主要的危險因子(OR:2.04,P=0.000)。喝酒(OR:1.48,P=0.037)及較高的BMI(OR:1.09, P=0.000)亦是大腸憩室症的危險因子。在所有大腸憩室憩室症(CD)病人中,有28.3% 是伴有腹痛症狀的大腸憩室疾病(DD),有顯著較高的BSRS-5 score。在單純IBS及單純有症狀大腸憩室疾病兩組間疼痛的持續時間、嚴重度及位置均無統計上顯著差異。 結論: 台灣人族群的大腸憩室症好發於右側。我們針對台灣人族群的研究中並未在大腸憩室症(不論是左側或右側)與大腸激躁症間看到關聯性。使用腹痛超過24小時的臨床症狀來鑑別IBS與有症狀的大腸憩室疾病的論述未能得到驗證。在IBS病人中有顯著較高的心理社會壓力。在較年輕的IBS患者中,大腸腺瘤的盛行率較低。年齡(大)是大腸憩室症最主要的危險因子。喝酒及肥胖會顯著增加大腸憩室症的風險。有症狀大腸憩室疾病的族群,須注意因慢性腹痛所造成的心理影響。 | zh_TW |
dc.description.abstract | Background:
Irritable bowel syndrome (IBS) is a common functional GI disorder. The clinical presentation and pathophysiologic mechanisms of IBS has overlap with some organic GI disease. Recent researches showed the presence of colonic diverticulosis (CD), especially left-sided diverticulosis, was associated with higher risk of IBS. However, conflicting findings were observed in the studies conducted in Asian population. Larger prospective studies are needed to confirm the association. Low grade inflammation and alteration in gut microbiota play important role in the pathophysiologic mechanism of symptomatic diverticular disease (DD). Recent studies have focused on the use of 5-ASA, antibiotics and probiotics in treating chronic diverticular disease. It is of clinical importance to distinguish IBS and chronic symptomatic diverticular disease to define the appropriate treatment. The effectiveness of abdominal pain lasting for more than 24 hours could discriminate IBS and DD had been proposed. Further validation is needed. Objectives: We conducted prospective study to 1. clarify the association between IBS and CD in Taiwanese population; 2. Validate the effectiveness of abdominal pain lasting for more than 24 hours in differentiating IBS and DD. Methods: We enrolled patients undergoing colonoscopy in single hospital. Questionnaire was applied to identify IBS patients (according to Rome III criteria) and to collect the characteristics of abdominal pain. We compared 1. the prevalence of CD in the IBS and non-IBS groups. 2. The prevalence of the clinical symptom of abdominal pain lasting for more than 24 hours in pure (no overlap) IBS and pure DD groups. Results: We initially enrolled 1502 subjects during March 2016 to November 2016 and 119 subjects met the exclusion criteria. A final total of 1383 subjects were enrolled for analysis. The mean age of the patients was 55.8±13.1 and the male to female ratio was 1.58:1. IBS was identified in 6.6% and CD was observed in 17.1% of the patients. Right-sided diverticulosis is predominant (69% of all CD). There was no statistically significant difference between the prevalence of whole CD (14.3% vs 17.3%, P=0.455), right-sided CD(8.8% vs 12.0%, P=0.359) and left-sided CD(2.2% vs 2.6%, P=0.435) in IBS and non-IBS groups. Significantly higher BSRS-5 score was observed in the IBS group. In younger (age<65) IBS patients, the prevalence of colonic adenoma was lower (OR:0.43, P=0.012). There was no significant difference between the prevalence of IBS in CD and non-CD groups (5.5% vs 6.8%, P=0.455). Older age was the most important risk factor for CD (OR:2.04,P=0.000). Alcohol consumption (OR:1.48,P=0.037) and higher BMI (OR:1.09, P=0.000) also increased the risk of CD. Within the whole diverticulosis group, abdominal pain was complained in 28.3% of the patients. Higher BSRS-5 score was observed in this subgroup (symptomatic diverticular disease). The pain duration, severity and location could not differentiate pure IBS and pure symptomatic DD in our study. Conclusions: In Taiwaness population, right-sided diverticulosis is predominant. The association between colonic diveticulosis and IBS was not observed in our study. The effectiveness of abdominal pain lasting for more than 24 hours in differentiating IBS and DD also could not be validated. IBS patients had higher psychosocial stress. Younger IBS patients had lower adenoma prevalence. Older age is the most important risk factor of CD. Alcohol consumption and obesity increased the risk of CD. Patients with symptomatic diverticular disease had higher psychosocial stress. | en |
dc.description.provenance | Made available in DSpace on 2021-05-13T06:43:12Z (GMT). No. of bitstreams: 1 ntu-106-P02421018-1.pdf: 1650615 bytes, checksum: 629fcedd8e0def0a967a5eee5c54ee2d (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 口試委員會審定書……………………………………………………………… i
中文摘要………………………………………………………………………… ii 英文摘要………………………………………………………………………… iv 第一章 研究背景………………………………………………………………… 1 第二章 研究方法………………………………………………………………… 4 第三章 研究結果………………………………………………………………… 7 第四章 討論………………………………………………………………… 10 第五章 未來展望………………………………………………………………… 14 第六章 論文英文簡述………………………………………………………………… 15 參考文獻…………………………………………………………………………… 20 圖1 大腸憩室症之分類及學術名詞義……………………………………………… 24 圖2 大腸憩室疾病可能之病生理機轉及其相關治療……………………………… 24 圖3 收案流程圖……………………………………………………………………… 25 腸胃道症狀及心理健康問卷………………………………………………………… 26 圖4收案流程圖---最終收案結果…………………………………………………… 30 表1病人特色………………………………………………………………………… 31 表2有大腸激躁症及無大腸激躁症群之比較……………………………………… 32 表3-1 大腸激躁症危險因子之多變數迴歸分析………………………………… 33 表3-2、表3-3大腸激躁症危險因子之多變數迴歸分析---依年齡分層……………… 34 表4有大腸憩室症及無大腸憩室症群組之比較…………………………………… 35 表5-1大腸憩室症危險因子之多變數迴歸分析……………………………………… 36 表5-2、表5-3大腸憩室症危險因子之多變數迴歸分析---依年齡分層…………… 37 表5-4無症狀大腸憩室症及有症狀大腸憩室疾病之比較………………………… 38 表5-5有症狀大腸憩室疾病危險因子之多變數迴歸分析………………………… 39 表6 大腸激躁症及有症狀大腸憩室疾病兩群組間腹痛特色之比較…… 40 表7 腹痛特色之迴歸分析………………………………………………………… 41 表8-1 大腸激躁症及有症狀左側/雙側大腸憩室疾病兩群組間腹痛特色之比較… 42 表8-2 大腸激躁症及有症狀右側大腸憩室疾病兩群組間腹痛特色之比較……… 43 | |
dc.language.iso | zh-TW | |
dc.title | 大腸憩室症與大腸激躁症之相關性研究 | zh_TW |
dc.title | The association between colonic diverticulosis and irritable bowel syndrome | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 劉俊人(Chun-Jen Liu),盧俊良(Ching-Liang Lu) | |
dc.subject.keyword | 大腸激躁症,大腸憩室症,憩室疾病,腹痛,盛行率, | zh_TW |
dc.subject.keyword | irritable bowel syndrome (IBS),colonic diverticulosis,diverticular disease,abdominal pain,prevalence, | en |
dc.relation.page | 43 | |
dc.identifier.doi | 10.6342/NTU201700358 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2017-02-08 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf | 1.61 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。